P物质受体拮抗剂在变应性鼻炎中的作用:卵清蛋白诱导的大鼠模型
该实验动物研究在34只雌性Sprague Dawley大鼠中建立卵清蛋白诱导的变应性鼻炎模型,比较阿瑞匹坦、抗组胺药和白三烯受体拮抗剂对鼻部症状及鼻和喉黏膜组织病理学改变的影响。结果显示抗组胺药和白三烯受体拮抗剂显著减少挠鼻和打喷嚏症状,阿瑞匹坦对鼻部症状无影响。阿瑞匹坦较过敏组显著减轻喉部假复层化,但其对喉部的作用尚未明确证实。
要点
- 抗组胺药和白三烯受体拮抗剂显著减少挠鼻和打喷嚏症状。
- 阿瑞匹坦对变应性鼻炎鼻部症状无影响。
- 阿瑞匹坦较过敏组显著减轻喉部假复层化。
核心结论
- 阿瑞匹坦在变应性鼻炎治疗中可提供组织病理学改变,但对鼻部症状无足够效果。
- 阿瑞匹坦对喉部的作用尚未明确证实。
研究设计与样本
- 实验动物研究,使用34只8-12周龄健康雌性Sprague Dawley大鼠,分为5组。
主要发现
- 抗组胺药和白三烯受体拮抗剂显著减少挠鼻和打喷嚏症状,而阿瑞匹坦对鼻部症状无影响。
- 喉部组织病理学检查中,过敏组与对照组相比发现显著差异。
- 喉部方面,阿瑞匹坦较过敏组显著减轻假复层化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Substance P is a peptide from the tachykinin family, which is found in peripheral and central nervous systems, causing vasodilation and increased secretion in the nasal mucosa. In this study, we aimed to investigate whether the experimental model of allergic rhinitis will cause allergic changes in the larynx and to compare the effects of aprepitant, a substance P antagonist, on nasal symptoms in allergic rhinitis, and histopathological changes in the nasal and laryngeal mucosa with antihistamine and leukotriene receptor antagonists (LTRA). STUDY DESIGN: An experimental animal study. METHOD: The study was carried out on 34 healthy 8-12 weeks old female Sprague Dawley rats in 5 groups. The rats in which an experimental allergic rhinitis model was created with ovalbumin were scored by observing their nasal symptoms, and nasal and laryngeal mucous membranes included in the study were evaluated histopathologically after medications. RESULTS: As a result of the analysis of the data obtained from the study, antihistamine and LTRA significantly reduced the symptoms of nose scratching and sneezing, while aprepitant did not affect nasal symptoms. In the histopathological examination of the larynx, effects that would make a significant difference were found in the allergy group when compared to the control group. On the larynx, aprepitant reduced pseudostratification significantly compared to the allergy group. CONCLUSION: Aprepitant provides histopathological changes in the treatment of allergic rhinitis, but does not have sufficient effect on nasal symptoms. The effect of aprepitant on the larynx has not been clearly demonstrated. LEVEL OF EVIDENCE: NA Laryngoscope, 133:2891-2897, 2023.
引用
- Becerik Ç, Karaca ÇT, Özcan Z, et al. The Role of Substance P Receptor Antagonists in Allergic Rhinitis: Ovalbumin-Induced Rat Model. Laryngoscope. 2023. PMID: 36856158. doi:10.1002/lary.30628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。